874279-84-2

Basic information

• Product Name: Benzene, 1-azido-3-fluoro-2-nitro-
• CAS NO: 874279-84-2
• Molecular Formula: C6H3FN4O2
• Molecular Weight: 182.114
• Mol File: 874279-84-2.mol

Chemical Properties

• CAS DataBase Reference: Benzene, 1-azido-3-fluoro-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-azido-3-fluoro-2-nitro-(874279-84-2)
• EPA Substance Registry System: Benzene, 1-azido-3-fluoro-2-nitro-(874279-84-2)

Safety Data

• Hazardous Substances Data: 874279-84-2(Hazardous Substances Data)

Upstream product

• 19064-24-5 2,6-difluoro-1-nitrobenzene 

Downstream Products

• 1046790-50-4 1-(3-azido-2-nitrophenyl)piperazine 
• 888016-50-0 1-[2-(3-azido-2-nitrophenoxy)ethyl]piperazine 
• 1046790-62-8 3-azido-2-nitrophenol 
• 1046790-73-1 1-azido-3-(2,2-diethoxyethoxy)-2-nitrobenzene 
• 874279-78-4 tert-butyl 4-(2,3-diaminophenyl)piperazine-1-carboxylate 
• 29270-55-1 4-fluoro-2,1,3-benzoxadiazole 
• 1046790-51-5 tert-butyl 4-(3-azido-2-nitrophenyl)piperazine-1-carboxylate 
• 1046790-85-5 4-{2-[4-(3-azido-2-nitrophenyl)piperazin-1-yl]ethoxy}-1H-benzo[d]imidazole-2(3H)-thione 
• 888016-52-2 4-{2-[4-(3-azido-2-nitrophenyl)piperazin-1-yl]ethoxy}-2-(trifluoromethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor

In this communication, we report the synthesis and characterization of a library of small molecule antagonists of the human gonadotropin releasing hormone receptor based upon the 2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole scaffold via Cu-catalysed

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Revisiting the Synthesis of 4,6-Difluorobenzofuroxan: A Study of Its Reactivity and Access to Fluorinated Quinoxaline Oxides

New quinoxaline 1,4-dioxide derivatives have been synthesized from novel fluorinated benzofuroxans such as 4-fluorobenzofuroxan, which is prepared for the first time. Furthermore, the preparation 4,6-difluorobenzofuroxan has been revisited because we were

1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS

The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions compr

2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor

Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.